TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 114,786 shares of the company's stock after selling 34,313 shares during the quarter. Ensign Peak Advisors Inc owned 0.34% of TransMedics Group worth $7,157,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. FORA Capital LLC bought a new stake in TransMedics Group in the fourth quarter worth $1,788,000. Frontier Capital Management Co. LLC acquired a new position in TransMedics Group in the 4th quarter valued at about $9,415,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of TransMedics Group by 40.1% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 7,290 shares of the company's stock worth $455,000 after purchasing an additional 2,086 shares during the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of TransMedics Group by 312.8% in the 4th quarter. Divisadero Street Capital Management LP now owns 158,480 shares of the company's stock valued at $9,881,000 after purchasing an additional 120,090 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in TransMedics Group by 8.3% during the fourth quarter. Cetera Investment Advisers now owns 8,260 shares of the company's stock worth $515,000 after buying an additional 634 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of research analyst reports. Oppenheimer upped their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Piper Sandler reissued an "overweight" rating and set a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Stock Down 0.8%

NASDAQ:TMDX traded down $1.03 during mid-day trading on Monday, hitting $120.56. The stock had a trading volume of 165,881 shares, compared to its average volume of 1,355,381. The stock has a 50-day simple moving average of $83.99 and a two-hundred day simple moving average of $75.82. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $4.08 billion, a PE ratio of 128.48 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.35 earnings per share. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares in the company, valued at approximately $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.